MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$2.74 USD
-0.07 (-2.49%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.74 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MREO 2.74 -0.07(-2.49%)
Will MREO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MREO
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
Other News for MREO
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
Mereo Biopharma Group Plc: A Buy Rating Backed by Strong Leadership and Promising Drug Pipeline
Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities